BIOMAT Database Logo BIOMAT Database Logo

Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. 1993

M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Department of Infectious Diseases 144, University of Copenhagen, Hvidovre Hospital, Denmark.

The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunodeficiency virus type 1 (HIV-1)-infected patients, whereas the NA response against autologous HIV-1 virus isolates is highly type-specific, motivated us to study the type- and group-specific NA responses generated upon presentation of escape virus, and the viral epitopes involved in the escape. Patients with demonstrable escape virus all developed group-specific NA, which were detectable after a delay and disappeared prior to disease development. The sera tested inhibited the binding of recombinant soluble gp120IIIB to cell-associated CD4, but group-specific virus neutralization required binding of NA to HIV-1 prior to viral attachment to target cells. Consecutive escape virus isolates were tested for sensitivity to neutralization by heterologous sera. Only minor differences were demonstrated, suggesting that the majority of the change in neutralization sensitivity is driven by the selective pressure of type-specific NA. Furthermore, no differences were observed in sensitivity to neutralization by anti-carbohydrate neutralizing monoclonal antibodies or the lectin concanavalin A, indicating a conserved nature of certain carbohydrate neutralization epitopes during escape. Finally the V3 sequence of three sets of consecutive virus isolates were analysed revealing amino acid mutations in V3 sequences of all escape virus isolates. The biological significance of these variations was confirmed further by the demonstration of changes in sensitivity to neutralization by anti-V3 monoclonal antibodies. These results strongly suggest a participation of the NA response against the V3 loop in the immunoselection of escape virus.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002241 Carbohydrates A class of organic compounds composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic

Related Publications

M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
June 1999, Journal of virology,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
June 2007, Journal of virology,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
January 2010, Virology,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
[Neutralizing antibodies and human immunodeficiency virus type 1 (HIV-1) infection].
February 2011, Virologie (Montrouge, France),
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.
November 1998, Journal of virology,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
December 2005, Proceedings of the National Academy of Sciences of the United States of America,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Viral evolution and escape during primary human immunodeficiency virus-1 infection: implications for vaccine design.
January 2008, Current opinion in HIV and AIDS,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.
August 2015, Journal of virology,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
October 1997, The Journal of infectious diseases,
M Arendrup, and A Sönnerborg, and B Svennerholm, and L Akerblom, and C Nielsen, and H Clausen, and S Olofsson, and J O Nielsen, and J E Hansen
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
March 1992, The Journal of infectious diseases,
Copied contents to your clipboard!